# Operational Guideline for ILI and SARI Surveillance

ILI and &SARI Surveillance Copyright © 2015 Health Protection Agency

All rights reserved.

No part of this book may be reproduced in any form by any electronic or mechanical means including photocopying, recording, or information storage and retrieval without prior permission in writing from Health Protection Agency, Maldives.

First Edition

February 2016

**\*** 

Health Protection Agency Maldives ISBN-13: 978-1-451-51000-X

Give feedback on the book at:

Email: flu@health.gov.mv

Website: www.hpa.gov.mv

Layout, Formatting and Cover by: Ibrahim Mifrah, Project Officer CDC Grant Project / Health Protection Agency

#### Table of Contents

Executive Summary 5 -	- 5
Objectives of ILI and SARI Surveillance	- 6
Sentinel Sites and Locations	- 6
Roles and Responsibilities	12
Case Definition ILI & SARI12	2-12
Specimen Collection and Processing13	6-15
Data Collecting and Reporting15	5-17
Annexes	3-37
Annex 1: Influenza Surveillance form	)-19
Annex 2: Sentinel ILI Surveillance Aggregated Data	)-20
Annex 3: Sentinel SARI Surveillance Aggregated Data	)-20
Annex 4: Weekly surveillance report format	-22
Annex 5: Weekly reporting format for sentinel sites23	-23
Annex 6: WHO guideline for preparation for Annual surveillance reort	-25
Annex 7a: SOP for influenza surveillance specimen collection, handling and packing	5-29
Annex 7b: Influenza specimen management flowchart	)-33
Annex 8: WHO performance indicators to measure quality of influenza sentinel surveillance	25
Annex 9: Data collection protocols for sentinel sites	
Annex 10: Specimen log form	

#### **Executive Summary**

Due to the large traffic of tourist arrival, congestion in the capital and the large number of migrant population makes Maldives a potential human mixing bowl for influenza and other respiratory viruses.

The government of Maldives has recognized that in order to establish an effective surveillance for early warning and outbreak response (EWAR), we need to have a more systematic Acute Respiratory Infection and particularly Severe Acute Respiratory Infection surveillance in place, with effective SOPs, adequate facilities for investigation, adequate staff and trainings for clinicians who are expected to report to surveillance staff.

The purpose of this guideline is to establish operational guidelines on influenza surveillance. This guideline assigns and informs respective staff/sentinel sites of their roles and responsibilities in the surveillance process. Additionally, these guidelines set the operational procedures of the entire influenza surveillance system as a whole.

The target audience of these guidelines is the staff and sentinel sites directly involved in the influenza surveillance process. This refers to Clinicians, Sentinel Surveillance Focal Point, Influenza Project Officer, Medical Laboratory Technologist/Technician at peripheral Sentinel Sites, The Public Health Laboratory and the National Surveillance Focal Point.

#### Objectives of ILI & SARI Surveillance

1. Describe the seasonality of influenza surveillance

2. Establish baseline levels of influenza, Influenza Like Illness and severe respiratory disease, which may be related to influenza and other respiratory pathogens.

3. Monitor unusual and unexpected events such as outbreaks of influenza during and outside the typical season.

4. Monitor which seasonal influenza viruses are circulating and detect novel viruses (eg. H5N1, H7N9).

5. Contribute to WHO vaccine strain selection

6. Identify and monitor groups at high risk of severe disease and mortality, in order to target education and prevention measures .

#### Sentinel Sites and locations

Sentinel Sites	SAR	ш
IGMH Male'	<ul> <li>✓</li> </ul>	<ul> <li>✓</li> </ul>
Hulhumale' Hospital	<ul> <li>✓</li> </ul>	<ul> <li>✓</li> </ul>
ADK Hospital	<ul> <li>✓</li> </ul>	
Senahiya		<ul> <li>✓</li> </ul>
Seenu Regional Hospital	<ul> <li>✓</li> </ul>	<ul> <li>✓</li> </ul>
Kulhudhuffushi Regional Hospital	<ul> <li>✓</li> </ul>	<ul> <li>✓</li> </ul>

Table:1 Sentinel Sites for ILI and SARI

Major objectives

of ILI & SARI

surveillance

**Operational Guidelines for ILI and SARI Surveillance** 

Health Protection Agency

#### Sentinel Sites

#### Responsibilities of Sentinel Sites

Responsibilities of

Clinicians

Roles and

Responsibilities of

Sentinel

Surveillance Focal

Point (SSFP)

The sentinel sites must have an influenza surveillance team comprising of clinicians, laboratory technicians, nurses and the surveillance focal point (SFP). Each of these members of the team should be assigned a specific role and responsibilities as follows:

#### Clinicians

1. Identification of patients that meet the ILI and SARI case definition in the guideline.

2. Daily recording of ILI and SARI cases at their respective sentinel sites.

3. Proper completion of Influenza Surveillance form for patients to be sent with the collected sample. (Annex 1: Influenza Surveillance Form).

4. Collection of respiratory specimens and sending to laboratory along with Influenza Surveillance form.

#### Sentinel Surveillance Focal Point (SSFP)

Each sentinel site should identify at least two focal points responsible for the routine surveillance operation. SSFP is selected among the hospital staff in consultation with the hospital administration, and the Influenza Project Officer will be the surveillance focal point in Health Protection Agency.

The SSFP should:

1. Collect and collate data on total number of patients who meet the ILI case definition from

OPDs and also count the total number of OPD cases seen every day or on a weekly basis.

Annex 2: Sentinel ILI Surveillance Aggregated Data

#### Annex 3: Sentinel SARI Surveillance Aggregated Data

3. Ensure sample collection of ILI patients from OPD

4. Ensure sample collection of all SARI patients from wards and ICUs.

5. Report all ILI and SARI cases to PHL (IGMH laboratory) on weekly basis by email or by fax if internet facility is not available.

6. Disseminate the reports and feedbacks received from NIC, PHL to the relevant health personnel (Clinicians, laboratory, nurses etc.).

7. Provide feedbacks from sentinel sites to Surveillance Unit and NIC, PHL (IGMH laboratory).

#### Influenza Project Officer (IPO)

1. Follow up with SSFP of each sentinel site on the number of samples taken for both SARI and ILI weekly.

2. Follow up with SSFP of each sentinel site on the total number of patients who meet the case definition for both SARI and ILI monthly.

3. Assurance of data quality in the database.

4. Preparing and disseminating the weekly and annual influenza surveillance reports to all stakeholders.

Annex4: Weekly surveillance report format

Annex5: Weekly reporting format for sentinel sites

#### Annex6: Annual Surveillance report format

5. Monitoring of NIC and sentinel sites.

6. Assess and identify gaps in influenza surveillance system.

7. Assist sentinel site to strengthen surveillance system.

8. Reporting weekly national surveillance data to regional and global influenza surveillance platforms.

(continued) Roles and Responsibilities of Sentinel Surveillance Focal Point (SSFP)

Roles and Responsibilities of the Influenza Project Officer **Operational Guidelines for ILI and SARI Surveillance** 

# Medical Laboratory Technologist/Technician at peripheral Sentinel Sites

1. Ensure all 'Influenza Surveillance forms' are provided and available at all wards and OPDs for notification and sample collection.

2. Provide all material for collecting respiratory specimens appropriately from patients meeting the case definitions to the OPDs and wards.

3. Ensure that all forms are filled out completely and accurately.

4. Ensure all respiratory specimens for ILI and corresponding forms are assigned with unique ID number.

5. Properly label, pack, store, and transport specimen to PHL (IGMH lab) according to the SOP for influenza surveillance specimen collection, handling and packing

### Annex 7a: SOP for influenza surveillance specimen collection, handling and packing

#### Annex 7b: SOP for sample collection - Laboratory

6. Shipment of specimen along with Influenza Surveillance form to PHL as per the pre-arranged shipment schedule.

7. Ensure test results are received from PHL and reported to the treating clinician on a weekly basis (Annex5: Weekly reporting format for sentinel sites).

#### Public Health Laboratory

#### National Influenza Center (NIC) at Indira Gandhi Memorial Hospital (IGMH)

#### Functions of the Public Health

Roles and

Responsibilities of

Medical

Laboratory

Technologist/

Technician at

peripheral

Sentinel Sites

Laboratory

Health Protection Agency

1. Serve as the technical and scientific focal point for sample collection and laboratory activities pertaining to ILI and SARI surveillance.

2. Coordinate all sample collection and transportation with all peripheral Sentinel sites.

3. Ensure all 'influenza surveillance forms' are provided and available at all wards and OPDs for notification and sample collection at IGMH and peripheral sentinel sites.

4. Provide all sentinel sites with protocols for sample collection, labeling, packing, storage, and transport of specimen to PHL according to the (Annex 4a).

5. Testing of samples of specimens for PCR at least one day per week.

6. Perform following activities on specimens received from sentinel sites:

i. Enter data from SARI & ILI Specimen collection forms received from all sentinel sites.

ii. Influenza virus typing and subtyping, using molecular methods (Real time RT-PCR / conventional PCR)

iii. Referral of any unsubtypable specimen to a designated WHO Collaborating Center.

iv. Receiving, archiving and storing original clinical specimens at -70°C for ILI/SARI for ten years.

v. Upload results in the web-based data management system.

7. Communicate the results of all individual confirmatory tests for ILI and SARI cases back to the designated SFP weekly (Every Sunday).

8. Share representative clinical specimen or virus isolates of seasonal influenza specimens with a WHO Collaborating Center (WHO-CC) twice a year.

9. Immediate sharing of information on any un-subtypable or suspect novel influenza viruses with a WHO Collaborating Center.

10. Participating in the WHO Global External Quality Assessment Project for the molecular detection of influenza viruses as well as in regional programs.

11. Provide initial and refresher training to sentinel sites on specimen collection, diagnosis, storage and transport.

12. Monitor sentinel sites to maintain quality of data and

**Operational Guidelines for ILI and SARI Surveillance** 

(continued)

Functions of the

Public Health

Laboratory

National Surveillance Focal Point (NSFP)

1. Managing computer database of ILI/SARI data.

Ensuring the dissemination of weekly and annual influenza surveillance reports to all stakeholders.

3. Establish a National influenza committee and meet on a monthly basis for detecting outbreaks, monitoring and improving influenza surveillance

4. Reporting weekly national surveillance data to regional and global influenza surveillance platforms.

5. Reporting to IHR focal point of any influenza novel strains cases as per the IHR requirements.

6. Provide initial and refresher training to sentinel sites on surveillance guidelines and procedures.

7. Review and update influenza surveillance guideline as needed.

8. Monitoring of NIC and sentinel sites.

9. Assess and strengthen influenza surveillance system.

10. Reporting to National Immunization Program on Influenza trends and burden for planning immunization or influenza.

Table2: Members of the National Influenza Committee

Roles and

Responsibilities

of the National

Surveillance Focal

Point (NSFP)

## National Surveillance Focal Point **Respiratory Physician** IGMH Lab Director

Laborotory Technologist

Epidemiologist

Immunization Focal Point

Disease Control Focal Point

National Influenza Committee

#### Role of National Immunization Program

1. Use influenza surveillance data in planning and preparing immunization plans for influenza, including:

- National Influenza Policy
- National Influenza Action Plan
- •Pandemic influenza vaccine deployment plan

#### **Case Definitions**

#### SARI

Page No. 12

-Any person with acute respiratory infection with;

i.Fever > 38° c

ii.Cough

iii.Hospitalized

iv.Onset within the past 7-10 days

#### ILI

-Any person with acute respiratory infection with;

i.Fever > 38∘ c

ii.Cough

iv.Onset within the past 7 days (best select patients with shorter duration or cases of fever within the last 2-4 days) Case Deinition for SARI (Severe Acute Respiratory Infections)

Role of National Immunization

Program

Case Deinition for ILI (Influenza-like Illness)

Health Protection Agency


#### Specimen Collection and Processing

#### ILI

**Operational Guidelines for ILI and SARI Surveillance** 

From each sentinel site a minimum of 10 samples per week


#### FLOW CHART – from sample collection to transferring to lab - ILI



#### SARI

From each sentinel site a minimum of 10 samples per week

#### FLOW CHART – from sample collection to transferring to lab - SARI



**Operational Guidelines for ILI and SARI Surveillance** 

Asking for patient

Consent

Data Collection

#### Patient Consent

As sample collection is for surveillance purpose and only verbal consent is required, patients may not expect to get results unlike tests done for diagnostic purposes. When taking samples be careful not to make the patient uncomfortable. Stress on the ease of this procedure and the benefits to the patients, but be realistic and do not be dishonest.

"To find what is causing your flu, I am using a swab to take sample from your nose and throat. With the sample a form, the details of your illness will be sent to IGMH laboratory. This test is free of charge. You may not get the result immediately as it is not needed for your treatment right now. But in case you get very sick and is admitted, we can trace the report from laboratory"

#### Data Collecting and Reporting

#### Data Collection

All the SARI and ILI sentinel sites should provide clinical detail of the patients using the Influenza Surveillance form. In all the sites (SARI and ILI) the doctors must complete the clinical detail of the patients. Nurses, clinical assistants and ward clerks can help the doctor to fill the form. For SARI sections A and C must be filled. For ILI the sections A and B must be filled. While sending the samples from the sentinel sites the laboratory technician must check the forms for data completeness, if it is not completed it should be sent back for the doctor to complete the form.

The original of the form must be send to the IGMH laboratory with the sample collected and a copy must be kept in the sentinel site. The laboratory information must be completed by the person who is receiving at IGMH and

(continued) Data Collection

Weekly SARI and

#### Weekly SARI and ILI data reporting

Page No. 16

IPO in IGMH should send result reports to all the sentinel sites each week on Sunday. This report includes test results of the patients from whom both ILI and SARI samples has been taken from in addition to indicating the positive samples with their sub typing.

#### Annex5: Weekly reporting format for sentinel sites

Weekly surveillance report for SARI includes aggregated number of patients who fit into SARI case definition for the week, number of deaths due to SARI and pneumonia for the week and total number of IPD patients for the week.

Weekly surveillance report for ILI includes aggregated number of patients whose samples have been collected for the week and total number of ILI cases for the week.

Annex 4: Weekly surveillance report format

#### Data Management

Data management is done by using MS Access. National Influenza Management System (NIMS) is maintained by NSFP.

#### Data Analysis

Data obtained for both ILI and SARI are analyzed and the following reports are generated:

- 1. Weekly reporting of results to sentinel sites.
- 2. Weekly update for FluID and FluNet application
- 3. Weekly surveillance report
- 4. Annual surveillance report

Data Management

Data Analysis

A surveillance system should undergo regular monitoring to routinely assess whether it is functioning efficiently and providing quality data to meet its stated objectives. Additionally, routine assessments should indicate areas in which personnel at the sentinel sites may need training and logistic support. Yearly, at least twice monitoring sentinel sites should be done.

#### Annex 8: Assessment tool to review sentinel sites

In addition should follow WHO standards for indicators to measure guality of influenza sentinel surveillance

Annex 9: WHO Standards for indicators to measure quality of influenza sentinel surveillance

#### Training

Clinicians - once a year refresher training for each sentinel site

Annual review meetings with all sentinel sites

Laboratory training - for sentinel sites on sample collection, packaging, storage and transport - once a year

Laboratory training for PHL – PCR, virology

Surveillance and Outbreak response - for central surveillance staff in health and agriculture sector

Indicators to assess the surveillance

Training

system

# **Operational Guidelines for ILI and SARI Surveillance**

Health Protection Agency

# ILI data reporting

#### Annexes

Annex 1: Influenza Surveillance form

Annex 2: Sentinel ILI Surveillance Aggregated Data

Annex 3: Sentinel SARI Surveillance Aggregated Data

Annex 4: Weekly surveillance report format

Annex 5: Weekly reporting format for sentinel sites

Annex 6: WHO guideline for preparation for Annual surveillance report

Annex 7a: SOP for influenza surveillance specimen collection, handling and packing

Annex 7b: Influenza specimen management flowchart

Annex 8: WHO performance indicators to measure quality of influenza sentinel surveillance

Annex 9: Data collection protocols for sentinel sites

Annex 10: Specimen log form

**Operational Guidelines for ILI and SARI Surveillance** 

Health Protection Agency

#### Annex 1: Influenza Surveillance form

		🕳 Inf	luenza	Surv	eilla	ance	9	
		Co.	mmunicabl Health P	e Disease S rotection A		lance		
Revised: Feb	ruary 2016	Min Min	istry of Heal			aldives		
SENTIN								
		(Complete or place ✓ap		-				
*1-ID-Car	d #:		2-Patie	nt Name:				
2 4	D-4	f Bisth OD / MM / YYYY	4-Sex:	□Male	D F	emale	5- Pregnant : □Yes □ No	
3-Age:	Dat	e of Birth : <u>DD / MM / YYYY</u>	- 6-Date	of consulta	tion/a	dmissio	n: <u>DD/MM/YYYY</u>	
7-* <u>Reside</u> (At the time			Atoll:	Islar	d:		Telephone no.:	
<ul> <li>As many This inclu</li> <li>The test severely</li> </ul>	flu-like illn ides collect results may ill. These re do these te	ing 2 samples from your nose and y not be available to you immedia esults are not usually required for ests if you consent to it. The infor	, some tests ar d throat for tes tely, but will be treating out-p	e being carrie ting. Tests are provided if t atients who a	ed out to e <u>free of</u> he clinio re not so	identify charge. ian requeverely i	the type of virus circulating in the commu ests it, particularly for admitted patients w I.	
ILI	$\checkmark$	Influenza Like Illness Surv	eillance - FO	OR OUTPAT	IENTS	ONLY		
SARI	$\checkmark$	Severe Acute Respiratory	Illness–GO	То В				
1-🗆 Histo	ory of fev	ver and □ Cough□Meas	ured tempe	erature ≥ 3	8 °C;	Temp	erature°C	
2-🗆 Onse	et of illne	ess with in last 10 days;	Onset date	e: DD / MM	/ <u></u>	or	no. of days	
3- Sample	s collecte	ed: □Throat □Nasal □Naso	-pharyngeal s	wab, $\Box$ othe	r	,	Date&Time,	
							S ONLY(place ✓appropriately)	
		he country with in the la	st 2 weeks:	□Yes □	No,	Where		
		ssion: DD / MM / YYYY						>
		d b) □Pediatric ward						SARI Cases only
		Tamiflu) use for present i	iiness: ⊔	Yes ⊔ I	NO			es
	-	edical Conditions		N:- h - t		No		Cas
		iratory disease b) Asth						R O
		eurological or neuromusc						SAI
		matological disorder h)[ noker k) □ Other, Specil		comprom	Iseu	1) 🗆 L	iver uisease	
		TED BY (for both SARI and						
C- FORIVI	CONNIPLE	TED BY (TOP DOLIT SART and	161)					
Name:		Designation		5	ignatu	re:	Date:	
D- Sampl	e Sent b	y Sentinel Site						
1-Date of sample sent from sentinel SITE to IGMH Lab:DD /MM / _YYYY								
2- Name a	ind Signa	ture :						
E- Compl	eted by	IGMH LAB	Lab Refe	rence#	Res	ults (n	nust be attached with this form	)
1-Sample received to IGMH Lab: Tes INO Date: DD / MM / YYY								
	2-Received Date: DD / MM / YYYY Type							
3-Sample condition:								
4. Signatu	re :				Ref	ndi K5		
F- DATA	ENTRY A	ND QUALITY CHECKS by	HPA Surve	illance				
Form Rece Name and		HPA: DD /MM / YYYY	Data entry Results en				outcome (to be followed up by HPA cases): a) □Discharged b) □D	
ivanie allu	Jigilatul	·	nesults ell	. y Lies L	1110	JANI		caur

#### Annex 2: Sentinel ILI Surveillance Aggregated Data

#### Weekly Aggregated data form for Influenza like-illness (ILI)

Sentinel Site Name: \_\_\_\_\_

Reporting Week No: \_\_\_\_\_, From (date) \_\_\_\_\_\_to (date)\_\_\_\_

	0 to <2	2 to <5	5 to <15	15 to <49	50 to <65	>=65	Total
Patients meeting ILI case definition							
Total outpatient visits							

Completed by

Name:\_\_\_\_\_\_ Designation:\_\_\_\_\_\_ date:\_\_\_\_\_

#### Annex 3: Sentinel SARI Surveillance Aggregated Data

Weekly Aggreg	ated data form for	severe acute respiratory infect	ions (SARI)
			(0, 11, 1)
Sentinel Site Name:		병 것 중 것 중 원	
Reporting Week No:	From(date)	to (date)	

	0 to <2	2 to <5	5 to <15	15 to <49	50 to <65	>=65	Total
Patients meeting SARI case definition							
SARI patients Sampled							
All hospital admissions							
			Complet	ed by			
Name:			Designatio	on:	date	31	

Health Protection Agency

#### Annex 4: Weekly surveillance report format

#### Weekly Influenza Surveillance Report

Week 1: 1 January to 2 January 2016

10 January 2016

**Operational Guidelines for ILI and SARI Surveillance** 

#### GENERAL SUMMARY

SITE and	Ш	SARI	TOTAL
RESULT			
IGMH			
INF A			
A H1N1 (Pandemic)			
H3			
Pending			
INF B			
Negative			
Hulhumale' Hospital			
INF A			
A H1N1 (Pandemic)			
НЗ			
Pending			
Negative			
ADK			
INF A			
A H1N1 (Pandemic)			-
INF B			
Negative			
Kulhudufushi Regional	Hospital		
Negative			
Grand Total			

#### POSITIVE CASES BASED ON AGE GROUPS

HOSPITALIZED FLU CASES BY AGE GROUP	NO OF POSITIVE
0-4 years	
5-24 years	
25-49 years	
50-64 years	
65+ years	

#### SARI CO-MORBIDITY (Disease burden) SUMMARY

#	Condition	Number o	f cases admitted in	
		wards	ICU/HDU	tota 1
1	Pregnant			
2	Chronic Respiratory Disease			
3	Asthma			
4	Diabetes			
5	Chronic Cardiac Disease			
6	Chronic neurological or neuromuscular disease			
7	Chronic renal disease			
8	Chronic haematological disorder			
9	Immune compromised			
10	Current smoker			
11	Liver disease			
12	Others			

#### DATA QUALITY SUMMARY

SITE	TOTAL SAMPLES	DATA COMPLETENESS %	AGE MISSING	CT Value
Α				
В				1
с				

**NOTE:** All data published in the Weekly Influenza Surveillance summary are up-to-date on the day of publication. The data provided do not reflect the total number of individuals who have been infected with the influenza virus in Maldives during the reporting period due to the following factors:

- 1. Many people ill with influenza-like symptoms do not seek medical care.
- 2. Many who do seek medical care are not tested for influenza.
- The IGMH Public Health Laboratory is limited by capacity to processing a maximum of 20 specimens per week.

The Influenza Surveillance Maldives is committed to serving you better by providing the most accurate, up-to-date influenza data available.

- 1. For general information on influenza, visit flu.delaware.gov or contact +960 300000
- 2. For questions regarding influenza vaccination, please call +960 30000

**Report Preparded by** 

Report Checked and Approved by

Health Protection Agency

**Operational Guidelines for ILI and SARI Surveillance** 

#### Annex 5: Weekly reporting format for sentinel sites

Sentinel Site		Week:	Year:		Total Re	ecord:
ILI/SARI	NID	Name	Age	Sex	Result	Subtype

#### Annex 6: WHO guideline for preparation for Annual surveillance report

#### Example of an Annual influenza surveillance system report

-Brief summary description of the epidemiological, virological, ILI and SARI data.

#### Description of the surveillance system

- Brieft description of how the data are collected and how the surveillance system is organized.

- Reporting procedures.

#### Epidemiological Surveillance

- Present the epidemiological data graphically.

- Describe the season in terms of starting date, duration of outbreak, intensity, and criteria for defining the start and end of the season.

- Age groups most affected.
- Differences in regions (if applicable).
- Comparison of this season to previous seasons.

#### SARI data

- Description and summary of influenza-associated SARI data collected by week admitted, age and gender.

- Co-morbidity among cases.
- Vaccine coverage among the SARI patients
- Fatal cases (if available)

#### Virological surveillance

- Present the virological data graphically.

- Description of how many influenza detections were done, as well as type and subtypes of influenza viruses.

- Describe differences in the distribution of viruses by age or severity.
- Summarize any notable changes from previous years.

**Operational Guidelines for ILI and SARI Surveillance** 

- Match between circulating viruses and strains covered by the vaccine.
- Vaccination coverage, if possible by age and/or risk groups.
- Antiviral resistance data (if available)
- Number of viruses tested for antiviral resistance.
- Results from testing.
- Number of viruses sent to WHO CC's for further testing.

#### Performance of the surveillance system

- Brief description of the system and its operations.
- Proportion of sentinel sites reporting to the national level weekly.
- Proportion of sentinel sites regularly submitting specimens for laboratory testing.
- Number of specimens sent from the sentinel sites.
- Timeliness of reporting from sentinel sites (or lag between data collection and reporting).
- Timeliness of reporting of results from laboratories to national level and to clinicallevel.
- Timeliness of data published in the weekly report.
- Proportion of weeks with reporting to FluNet and FluID and/or other reporting systems.
- Aberrations observed trends/data.

Annex 7a: SOP for influenza surveillance specimen collection, handling and packing

#### 1. Purpose and Scope:

This procedure will be used to collect throat swab, nasal swab and nasopharyngeal swab for Influenza testing.

#### 2. Responsible Staff:

Clinician, nurse and any other designated person.

#### 3. Materials Required

Reagents and Materials required:

- · Powder free gloves
- Mask

 UTM<sup>™</sup> Sample collection kit (3ml) ), containing collections swabs and collection vial with 3mL of UTM

Note: UTM<sup>™</sup> sample collection kit should be stored within 2°C-25°C before sample collection.

#### 4. Protocol:

#### Infection Control Measurements

· Clinical samples should be collected by doctor, nurse or

designated person.

• Wash your hands properly with soap or hand scrub before and after sample collection.

· All clinical samples have to be collected wearing appropriate PPE.

- Use Latex or nitrile disposable gloves.
- Wear laboratory coat/disposable apron.

• Use protective eye wear (goggles) face mask or face shields

- After sample has been collected, propoerly cap the vial.
- Remove the goggles, mask, coat/apron and gloves.

· Perform Hand Hygene again

**Operational Guidelines for ILI and SARI Surveillance** 

**Throat Swab** 

Nasal Swab

Materials Required

Purpose and

Scope

**Responsible Staff** 

Protocol

Infection Control Measurements

#### Throat Swab

•Have the patient lying or sitting on the bed with the head of the bed elevated.

•Hold the tongue away with tongue depressor.


·Locate the posterior pharynx, tonsillar region of throat behind uvula.

•Avoid swabbing soft palate; do not touch tongue.

•Rub the tonsils and posterior pharynx back and forth with tipped plastic swab.

Place the swab into the UTM vial.

•Label the UTM with the patient's first and last name and the date of collection, specimen type, age and sex.



Rub the swab across the tonsillar areas and the posterior pharynx, specifically targeting any inflamed areas

#### Nasal Swab

Tilt patient's head back gently and steady the chin.

· Insert the swab into nostril and rotate firmly against the midline nasal septum (to ensure swab contains cells as well as mucus)

the date of collection, specimen type, age and sex.

 After the swab is removed from the patient, place it inside the UTM vial, with the swab tip at the top of the conical portion of the transport tube, rest the swab shaft against the rim of the tube and snap the shaft at the pre-scored break point. Hold the tube opening away from your face.

Page No. 28

•Have the patient lying or sitting on the bed with the head of the bed elevated.

•Gently bend the swab (while inside the sterile package) to give it a slight arc.

•Aseptically remove the sterile swab from package.

-Tilt patient's head gently back (about  $70^\circ)$  and steady the chin

•Insert the swab into one nostril 4-6cm. The rule of the thumb to determine when swab is placed properly.

•Insert swab to one-half the distance from the tip of the nose to the tip of the earlobe.


•Press the swab tip on the mucosal surface of the mid-inferior turbinate.

•Rub swab back and forth about 5 times.

•Leave the swab in place for a few seconds to absorb cells.

•Slowly withdraw the swab with a rotating motion.

•Place the tip of the swab into the UTM vial, break the swab at scored line and close the vial tightly.




A sterile swab is passed gently through the nostril and into the nasopharynx

(continued)

Nasal Swab


Nasopharyngeal Swab







**Operational Guidelines for ILI and SARI Surveillance** 

Health Protection Agency







#### Contacts

**Operational Guidelines for ILI and SARI Surveillance** 

Health Protection Agency

Reports from IGMH lab should be sent to:


Ibrahim Nishan Ahmed	(nishan.ahmed@health.gov.mv	•
IGMH medical records		•
IGMH laboratory	(lab@igmh.gov.mv)	Contacts
Dr. Milza	(abmilza.m@gmail.com)	•
WHO reference lab		• • •

Annex 8: WHO performance indicators to measure quality of influenza sentinel surveillance

To evaluate the efficiency and success of the system, a number of process indicators and outcome indicators have been established.


#### Timeliness

Several time intervals are appropriate for routine measurement as quality indicators:




#### Completeness






#### Audit

Regular field evaluations and audits at facility level of a subset of medical records to ensure the following:



#### Data to be followed and observed for aberrations over time

**Operational Guidelines for ILI and SARI Surveillance** 



#### Annex 9: Data Collection Protocols for Sentinel Sites

#### 1. Indhira Gandhi Memorial Hospital (IGMH)

- Samples taken from all SARI patients
- Samples for ILI:

Department	Dartment Collection Days		Total samples collected per week	
Pediatric OPD	Sunday – Thursday	Two	Ten	
Medicine OPD	Tuesday	Five	Five	
General OPD	Sunday – Thursday	Two	Ten	

#### 2. ADK Hospital

- Samples taken from all SARI patients.
- No samples collected for ILI

#### 3. Hulhumale' Hospital

- Samples taken from all SARI patients.
- Samples for ILI:

Department	Collection Days	Number of samples per day	Total samples collected per week
Pediatric OPD	Sunday – Thursday	Two	Ten
Medicine OPD	Sunday – Thursday	Two	Ten
General OPD	Sunday – Thursday	Two	Ten

#### 4. Kulhudhufushi Regional Hospital

- Samples taken from all SARI patients.
- Samples for ILI:

Department	Collection Days	Number of samples per day	Total samples collected per week	
Pediatric OPD	Sunday – Thursday	Two	Ten	
Medicine OPD	Medicine OPD Sunday – Thursday		Ten	
General OPD	Sunday – Thursday	Two	Ten	

Health Protection Agency

**Operational Guidelines for ILI and SARI Surveillance** 

#### Annex 10: Specimen log form



No. D	Date			Fever	Cough	Sample Taken (Y/N)	Type of Sample		
		ID Number	Age				Nasal	Throat	Nasopharyngea
1				1	- X.		192	10	
2				2	- W	- W	141	2	2
3				1.2	- Q	- G -	4	3	
4				1. U. I.	- Q	- 12	1	- 93 - 93	2
5					- U			- v -	
6				- w.	- e		140	10	
7				2	- V.	- 2	1.00	- 22	2
8				1.2	- 22	¥.	4	2	
9				- Q. 1	- V -	ų s	4	- 22 -	
10					- Q	- U	1	- V	3
11					~			~	~
12				- v.	- e			- V.	
13				- V.	- V.	2	1.00	×.	1
14				0	- W	- V	14	- 24	1
15					5	- U	4	1	
16					- Q	5	1	- V.	1.1.1
17					- V	~			
18				1.2	- W		14		
19				1.00	- Q.	0	102	U.	
20				- V - 1	- W	- V	141	- Ø.	4
21				- V -	- Ç	- Q	~	2	
22					÷.	5	1	. V.	5
23				- v.	~	~			1.00
24				1.0	~	- v	1.0	- W.	
25				2	2	- <i>S</i>		υ.	2
26				- Q - 1	- U	~	4	- Q.	÷.
27				1.2	- S	- Q	~	2	~
28				- V -	ų.	- U		U.	4
29				~	- V.	2	- V.		
30				~			~		

#### \*\*Please tick the respective boxes